S&P 500 Futures
(0.11%) 5 333.25 points
Dow Jones Futures
(0.03%) 40 151 points
Nasdaq Futures
(0.20%) 18 672 points
Oil
(-0.42%) $79.72
Gas
(0.95%) $2.65
Gold
(1.16%) $2 445.50
Silver
(3.23%) $32.27
Platinum
(0.08%) $1 090.90
USD/EUR
(0.00%) $0.920
USD/NOK
(-0.11%) $10.66
USD/GBP
(0.02%) $0.787
USD/RUB
(-0.62%) $90.41

Realtime updates for Iovance Biotherapeutics [IOVA]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
51.02%
return -17.18%
SELL
38.00%
return 25.94%
Last Updated17 May 2024 @ 16:00

-1.82% $ 10.24

BUY 3857 min ago

@ $10.27

Issued: 17 May 2024 @ 14:04


Return: -0.29%


Previous signal: May 17 - 13:33


Previous signal: Sell


Return: -0.77 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.35% compare to its pairs and should correct upwards.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells...

Stats
Today's Volume 4.51M
Average Volume 8.04M
Market Cap 2.87B
EPS $0 ( 2024-05-14 )
Next earnings date ( $0 ) 2024-08-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -5.66
ATR14 $0.414 (4.05%)
Insider Trading
Date Person Action Amount type
2024-04-15 Vogt Frederick G Buy 20 834 Common Stock
2024-04-15 Vogt Frederick G Sell 8 851 Common Stock
2024-04-15 Vogt Frederick G Sell 20 834 Restricted Stock Units
2024-04-15 Graf Finckenstein Friedrich Buy 2 812 Common Stock
2024-04-15 Graf Finckenstein Friedrich Sell 1 427 Common Stock
INSIDER POWER
94.70
Last 99 transactions
Buy: 13 607 426 | Sell: 449 378
Correlation (AI algo v.1.1b): Undervalued: 0.35% $10.26 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.03 (neutral)
Short: -0.90 (strong negative)
Signal:(48) Neutral

Iovance Biotherapeutics Correlation

10 Most Positive Correlations
LRMR0.904
EQ0.9
CFLT0.898
TARA0.883
NTWK0.864
FROG0.86
TRMB0.86
CLBT0.855
PXLW0.853
ALRM0.852
10 Most Negative Correlations
BLKB-0.908
SSRM-0.874
CAR-0.842
FINW-0.842
DSWL-0.827
CYAN-0.825
EGAN-0.823
BIOL-0.821
SGLY-0.817
WTER-0.812

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Iovance Biotherapeutics Correlation - Currency/Commodity

The country flag 0.00
( neutral )
The country flag 0.01
( neutral )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )
The country flag 0.38
( neutral )
The country flag -0.35
( neutral )

Iovance Biotherapeutics Financials

Annual 2023
Revenue: $1.19M
Gross Profit: $-31.94M (-2 686.12 %)
EPS: $-1.890
FY 2023
Revenue: $1.19M
Gross Profit: $-31.94M (-2 686.12 %)
EPS: $-1.890
FY 2022
Revenue: $0
Gross Profit: $-21.14M (0.00 %)
EPS: $-2.45
FY 2021
Revenue: $0.00
Gross Profit: $0.00 (0.00 %)
EPS: $-2.20

Financial Reports:

No articles found.

Iovance Biotherapeutics Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators